According to Zhitong Finance App News, Minimally Invasive Brain Science (02172) announced its annual results for the year ended December 31, 2023. The group achieved revenue of 666 million yuan (RMB, same below), an increase of 21.61% over the same period last year; profit attributable to shareholders was 146 million yuan, and losses due to shareholders were 21.755 million yuan during the same period last year, turning a loss into profit from the previous year; basic profit of 0.25 yuan per share; it is proposed to distribute a final dividend of HK$0.11 per share.
According to the announcement, the increase in revenue is mainly due to: various market-share leading products (including Tubridge blood-flow guided dense mesh stents, Bridge vertebral artery rapamycin targeted elution stents systems and NuMen detembolizing spring rings, etc.) continued to explore the empty hospital and sink market, further consolidated their competitive advantage and achieved significant revenue growth; newly approved products in 2022 (including Neurohawk intracranial embolization stents, Diveer intracranial balloon dilatation catheters, etc.) accelerated hospital access and contributed to the Group's revenue growth; overseas business continued to grow rapidly in Revenue of 31.7 million yuan was obtained in fiscal year 2023.